Latest information on COVID-19
Support teaching, research, and patient care.
Currently, Professor of Pediatrics (Neonatology). EMERITUS, Stanford University School of Medicine, Vinod K. Bhutani, M.D. FAAP a graduate from Armed Forces Medical College, India. He is board-certified Neonatologist and formally trained as a pulmonary physiologist, transformational bilirubin biologist and pediatric health policy expert. His primary career aims encompass distinct investigative domains: i) clinical translation of basic science; (ii) elucidation of predictive biomarkers for maternal-child health; (iii) design of affordable, high quality practical biotechnologies; (iv) operationalize systems application through novel modes of healthcare access; and (v) prevention of newborn brain damage; specifically, of bilirubin-neurotoxicities and broncho-pulmonary dysplasia. In addition, he is an avid advocate for maternal, neonatal and child well-being. He is the Co-Founder and Executive Director for the Consortium for Universal Rhesus disease Elimination (CURhE), Co-Founder of NeoDesign (Neonatology) and Co-Chair of the Audrey K. Brown Kernicterus Symposium at the Pediatric Academic Societies. His awards include the Fellow of the National Neonatology Forum of India and its Lifetime Achievement Award (2014), the Lifetime Achievement Award of Indian Academy of Pediatrics (Neonatology, 2019), the Neonatal Landmark Award by the American Academy of Pediatrics (Section on Neonatal-Perinatal Medicine, 2013) and the “Legend in Neonatology” by MidAtlantic Neonatology, NeoForum (2010). He has pioneered universal pre-discharge neonatal bilirubin screening, global maternal Rhesus blood type screening, point-of-care G6PD testing, neonatal hemolysis screening, assays for bilirubin binding and effective prescription of phototherapy. In addition, he has collaborated in the development novel neonatal thermal support (Embrace device), computerized neonatal function testing (pulmonary graphics) and adaptive oxygen delivery.
Economic considerations for a national scale-ip
Newborn citizens of a Nation
Bilirubin Brain Injury
Saving Newborn Lives
Global Prevention of Rh disease
All women and newborns
Heath and Society
PFIIS, Stanford University
Community-based clinical diagnostic tool-kits
The Programme for Paeditric Research
Clinical Evaluation of Exothermic Devices for Neonatal Warming
Preterm and Low birth Weight Infants World-wide
Translation and bench research for affordable devices that enable remote monitoring of neonatal vital signs, laboratory assays using nanotechnology (specifically, G6PD enzyme, bilirubin, unbound bilirubin and bilirubin binding capacity) and neonatal thermoregulation. We engage pro-actively in public health policies that rely on novel technologies, population data and development of clinical utility decision making tool-kits for global implementation.
Clinical Performance of the Embrace Isothermal Mattress
The purpose of this pilot study is to evaluate the performance of a new warming technology
(Embrace Isothermal Mattress) during the thermal weaning of premature infants from incubators
to open cribs. The investigators aim to study the Embrace Isothermal Mattress over a 24-hour
period before the infant is transitioned out of the incubator.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nathan Meng, .
View full details
Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns
In South Africa, healthy term newborns are usually discharged early (<72 hours after
delivery). Many studies have shown that hospital readmission rates have increased with this
practice, and jaundice or hyperbilirubinemia is the most common cause of readmission of
newborns. Peak serum bilirubin levels usually occur on postnatal days 3-5, by when many have
already been discharged putting the infant at increased risk of severe hyperbilirubinemia.
Severe neonatal jaundice still constitutes an important cause of neonatal mortality and
morbidity in Africa. Screening all newborns for the risk of severe hyperbilirubinemia before
hospital could help in early identification of hyperbilirubinemia and early intervention and
potentially prevent unwanted consequences like bilirubin induced neurological dysfunction.
However, there are conflicting recommendations on the use of universal transcutaneous
bilirubin screening for jaundice in all newborns before hospital discharge.
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
Most preterm newborns are managed by phototherapy to reverse hyperbilirubinemia with the
intent to prevent bilirubin neurotoxicity. A threshold-based relationship between a specific
total bilirubin level and need for intervention has been elusive. This is most likely due to
other biomarkers such as hemolysis, developmental maturation, concurrent illnesses, or even
interventions, may impede bilirubin/albumin binding. The over-prescription of phototherapy
has impacted clinical and family-centered care, and in the extreme preterm infants, it may
have augmented their risk of mortality. Thus, the opportunity to individualize phototherapy
in in order to reduce its use is unique. The investigators have assembled a transdisciplinary
team to examine critical unanswered questions including the role of bilirubin binding
capacity (BBC) of an individual during the first week of life in the context of clinical
modifiers and antecedents for a domain of bilirubin-induced neurologic disorders, that
includes neuro-anatomical, hearing, visual and developmental processing impairments. In this
study, the investigator will evaluate two new innovative nanotechniques to quantify bilirubin
load for the first time in the context of a clinical decision algorithm to identify those
most at risk for any bilirubin-related neurotoxicity. The investigators anticipate that
knowledge gained from this study will lead to ethically testable hypotheses to individualize
the prescription of phototherapy.
Point-of-Care System for Determination of Bilirubin Capacity in Neonates
The aims of this project are to validate the performance of the miniaturized and modernized
hematofluorometer that measures bilirubin capacity into a product and is suitable for
operation in various point of care environments when encountering confounding direct
bilirubin, to complete the development of easy to use sample handling disposables, and to
verify the performance of the system for samples from a specified population of neonates.